Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer

John F.R. Robertson; Robert J. Paridaens; Jasmine Lichfield; Ian Bradbury; Christine Campbell

doi:10.1016/j.ejca.2020.11.038

Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer

John F.R. Robertson, Robert J. Paridaens, Jasmine Lichfield, Ian Bradbury, Christine Campbell

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	19-28
Number of pages	10
Journal	European Journal of Cancer
Volume	145
DOIs	https://doi.org/10.1016/j.ejca.2020.11.038
Publication status	Published - Mar 2021
Externally published	Yes

ASJC Scopus Subject Areas

Oncology
Cancer Research

Keywords

1st line endocrine therapy
3rd generation AIs
Advanced breast cancer
HR positive
meta-analyses of RCTs
tamoxifen

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2020.11.038

Fingerprint

Dive into the research topics of 'Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer'. Together they form a unique fingerprint.

Cite this

Robertson, J. F. R., Paridaens, R. J., Lichfield, J., Bradbury, I., & Campbell, C. (2021). Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer. European Journal of Cancer, 145, 19-28. https://doi.org/10.1016/j.ejca.2020.11.038

Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer. / Robertson, John F.R.; Paridaens, Robert J.; Lichfield, Jasmine et al.
In: European Journal of Cancer, Vol. 145, 03.2021, p. 19-28.

Research output: Contribution to journal › Article › peer-review

Robertson, JFR, Paridaens, RJ, Lichfield, J, Bradbury, I & Campbell, C 2021, 'Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer', European Journal of Cancer, vol. 145, pp. 19-28. https://doi.org/10.1016/j.ejca.2020.11.038

@article{d6832941758f4aca863df88dfeef788b,

title = "Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer",

keywords = "1st line endocrine therapy, 3rd generation AIs, Advanced breast cancer, HR positive, meta-analyses of RCTs, tamoxifen",

author = "Robertson, {John F.R.} and Paridaens, {Robert J.} and Jasmine Lichfield and Ian Bradbury and Christine Campbell",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2021",

month = mar,

doi = "10.1016/j.ejca.2020.11.038",

language = "English",

volume = "145",

pages = "19--28",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer

AU - Robertson, John F.R.

AU - Paridaens, Robert J.

AU - Lichfield, Jasmine

AU - Bradbury, Ian

AU - Campbell, Christine

PY - 2021/3

Y1 - 2021/3

KW - 1st line endocrine therapy

KW - 3rd generation AIs

KW - Advanced breast cancer

KW - HR positive

KW - meta-analyses of RCTs

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=85098882053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098882053&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2020.11.038

DO - 10.1016/j.ejca.2020.11.038

M3 - Article

C2 - 33418233

AN - SCOPUS:85098882053

SN - 0959-8049

VL - 145

SP - 19

EP - 28

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer

ASJC Scopus Subject Areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this